Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|June 14, 2011
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancerLeora Horn, Zhiguo Zhao, Alan Sandler, et al.
Cancer Research|December 6, 2006
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancerCarolyn Cao, Jeffrey M Albert, Ling Geng, et al.
Plos One|February 3, 2021
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patientsNamrata S Patil, Wei Zou, Simonetta Mocci, et al.
Expert Review of Respiratory Medicine|December 13, 2019
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with <i>EGFR</i> mutationsMartin Reck, Geetha Shankar, Anthony Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2010
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancerAlan Sandler, Jing Yi, Suzanne Dahlberg, et al.
The Oncologist|January 25, 2015
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancerJuneko E Grilley-Olson, Vicki L Keedy, Alan Sandler, et al.
The New England Journal of Medicine|January 11, 2002
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancerJoan H Schiller, David Harrington, Chandra P Belani, et al.
The New England Journal of Medicine|December 15, 2006
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerAlan Sandler, Robert Gray, Michael C Perry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapiesRamaswamy Govindan, John Crowley, Lee Schwartzberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2010
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599Julie R Brahmer, Suzanne E Dahlberg, Robert J Gray, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|June 14, 2011
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancerLeora Horn, Zhiguo Zhao, Alan Sandler, et al.
Cancer Research|December 6, 2006
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancerCarolyn Cao, Jeffrey M Albert, Ling Geng, et al.
Plos One|February 3, 2021
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patientsNamrata S Patil, Wei Zou, Simonetta Mocci, et al.
Expert Review of Respiratory Medicine|December 13, 2019
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with <i>EGFR</i> mutationsMartin Reck, Geetha Shankar, Anthony Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2010
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancerAlan Sandler, Jing Yi, Suzanne Dahlberg, et al.
The Oncologist|January 25, 2015
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancerJuneko E Grilley-Olson, Vicki L Keedy, Alan Sandler, et al.
The New England Journal of Medicine|January 11, 2002
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancerJoan H Schiller, David Harrington, Chandra P Belani, et al.
The New England Journal of Medicine|December 15, 2006
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerAlan Sandler, Robert Gray, Michael C Perry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapiesRamaswamy Govindan, John Crowley, Lee Schwartzberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2010
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599Julie R Brahmer, Suzanne E Dahlberg, Robert J Gray, et al.
Pageof 9